Research in life extension and anti-aging has been underway for decades, but most projects remain in the preclinical or early clinical stages. Nevertheless, several areas are now approaching more advanced phases of development, and their results could significantly reshape the longevity industry and improve the quality of life for millions of people.
- Senolytic Drugs: Eliminating Aging Cells
One of the most promising areas involves senolytic drugs, which target and eliminate senescent cells—aging cells that accumulate in the body and damage tissues.
- According to longevity advocate Aubrey de Grey, senolytic studies currently in Phase II clinical trials may soon progress to Phase III.
- Unity Biotechnology, Inc. is a leading company in this field, developing senolytic therapies for age-related diseases.
- In 2020, the company’s osteoarthritis drug UBX0101 failed in Phase II trials, leading the company to shift focus toward ophthalmological diseases.
- In 2021, UBX1325, a Bcl-xL inhibitor, successfully completed Phase I and moved into Phase II trials for the treatment of age-related macular degeneration and diabetic macular edema.
- Oisín Biotechnologies is developing a gene therapy approach to precisely remove senescent cells from DNA. Their SENSOlytics® technology was included in the MIT Technology Review list of breakthrough technologies in 2022.
- Therapies Based on Systems Biology and Artificial Intelligence
BioAge Labs uses a platform combining systems biology and artificial intelligence to identify molecular drivers of age-related diseases.
- In 2021, clinical trials began for BGE-117, a drug targeting unexplained anemia of aging.
- Another compound, BGE-175, is designed to rejuvenate the immune system in patients over 60 and reduce the severity of COVID-19.
- These therapies could potentially be applied to a wider range of age-related diseases.
Meanwhile, MyMD Pharmaceuticals is developing an immunotherapy for aging and autoimmune diseases. Their drug MYMD-1® regulates inflammatory cytokines without damaging cells and can cross the blood–brain barrier, making it potentially useful for treating neurological disorders.
- Gene Technologies: CRISPR/Cas
CRISPR/Cas gene editing is one of the most anticipated technologies in the longevity industry. Although it has been studied for about a decade, only a limited number of clinical trials in humans have been approved so far.
- Regeneron and Intellia Therapeutics conducted a Phase I trial for the rare disease transthyretin amyloidosis. In six patients, the concentration of the pathological protein decreased by 50–90%, with no significant side effects observed.
- Excision BioTherapeutics received approval for Phase I/II clinical trials of an HIV therapy using CRISPR/Cas, delivered intravenously.
- Moderna is developing personalized mRNA cancer vaccines, designed individually for each patient.
Although these approaches are still in early stages, they demonstrate enormous potential for treating age-related and genetic diseases.
- Improving Quality of Life: Rare and Age-Related Diseases
Research aimed at improving quality of life focuses on rare, immune, chronic, and age-related diseases.
- Sanofi currently has more than 100 drugs in development across oncology, neurology, immunology, and blood disorders, with 28 in Phase III clinical trials.
- Retrotope is developing a therapy targeting cell degeneration caused by lipid peroxidation. Its drug RT001 is in late-stage trials for ALS, Friedreich’s ataxia, and infantile neuroaxonal dystrophy.
- Vertex Pharmaceuticals is developing VX-880, a stem-cell therapy for type 1 diabetes. In the first treated patient, the need for insulin injections nearly disappeared.
- Researchers at Osaka University successfully tested corneal transplantation using induced pluripotent stem cells (iPS cells), a breakthrough that could potentially help over 12 million people suffering from corneal stem cell deficiency.
- Treatments for Neurodegenerative Diseases
Special attention is being paid to Alzheimer’s and Parkinson’s diseases, two major age-related neurological conditions.
- Eli Lilly is studying donanemab, an antibody that alters the structure of amyloid-beta, in Phase II trials involving patients with early-stage Alzheimer’s disease. Interim results have shown slower cognitive decline.
- For Parkinson’s disease, researchers are exploring ways to remove the neurotoxic protein alpha-synuclein, although definitive positive results have not yet been achieved.
- For multiple sclerosis, several therapies have already been approved, while new treatment approaches continue to be studied.
- Technological and Genetic Innovations
Several technological breakthroughs are also contributing to advances in life extension and regenerative medicine:
- 3D bone printing: Particle3D’s P3D Bone PSI technology creates personalized bone implants based on a patient’s CT or MRI scans.
- CRISPR gene editing in embryos: experimental studies are exploring genome editing to prevent hereditary diseases such as beta-thalassemia. These experiments raise serious ethical questions but continue to be investigated.
Conclusions
Although most research in life extension and healthspan improvement remains in early stages, several areas are already producing promising clinical results and breakthrough technologies, including:
- senolytic therapies
- gene and cell-based approaches
- immunotherapy
- stem-cell therapies
- innovations in the treatment of neurodegenerative and rare diseases
These developments demonstrate real progress in the longevity industry and open the door to new methods for combating aging and improving the quality of life for millions of people.